Pharmaceuticals Market Research Reports & Industry Analysis

Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.

The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.

The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.

Found 13670 publications
Hepatitis Drugs Markets in China US$ 4,000.00

China's demand for hepatitis drugs has grown at a fast pace in the past decade. In the next five years, both production and demand ... environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2003, 2008 and ...

Apr, 2014 170 pages
COPD Drug Market Opportunity & Clinical Pipeline Analysis US$ 2,200.00

... dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the ... , it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. “COPD Drug Market Opportunity & Clinical Pipeline Analysis” Report ...

Apr, 2014 590 pages
Wroclawskie Centrum Badan EIT+ Sp. z o.o. - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Wroclawskie Centrum Badan EIT+ Sp. z o.o.’s pipeline products ...

Mar, 2014 16 pages
Visceral Pain - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Visceral Pain - Pipeline Review, H1 2014’, provides an overview of the Visceral Pain’s therapeutic pipeline. This report provides ... type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

Mar, 2014 41 pages
Serendex Pharmaceuticals A/S - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Serendex Pharmaceuticals A/S’s pipeline products ...

Mar, 2014 23 pages
Orphazyme ApS - Product Pipeline Review - 2014 US$ 1,500.00

... all the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Orphazyme ApS’s pipeline products ... drug targets and therapeutic classes in the Orphazyme ApS’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 25 pages
Natco Pharma Limited - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Natco Pharma Limited’s pipeline products Reasons ... of focus Identify new drug targets and therapeutic classes in the Natco Pharma Limited’s R&D portfolio and develop key strategic initiatives to reinforce ...

Mar, 2014 27 pages
ImmunGene, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the ImmunGene, Inc.’s pipeline products ... drug targets and therapeutic classes in the ImmunGene, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas Exploit ...

Mar, 2014 19 pages
Colon Carcinoma - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Colon Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Colon Carcinoma’s therapeutic pipeline. This report provides ... , along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

Mar, 2014 45 pages
Binge Eating Disorder - Pipeline Review, H1 2014 US$ 2,000.00

... Review, H1 2014’, provides an overview of the Binge Eating Disorder’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ...

Mar, 2014 56 pages
Apceth GmbH & Co. KG - Product Pipeline Review - 2014 US$ 1,500.00

... description, key information and facts, and its locations and subsidiaries The report reviews current pipeline of Apceth GmbH & Co. KG’s human therapeutic ... the dormant and discontinued pipeline projects Latest company statement Latest news and deals relating to the Apceth GmbH & Co. KG’s pipeline products ...

Mar, 2014 21 pages
Advanced Accelerator Applications - Product Pipeline Review - 2014 US$ 1,500.00

... action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with ... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Advanced Accelerator Applications’s pipeline products Reasons ...

Mar, 2014 21 pages
Denmark Pharmaceuticals and Healthcare Report Q2 2014 US$ 1,295.00

... FREE quarterly updates BMI View: Although Denmark's pharmaceutical market is relatively small compared to other Western European countries, the demand for high quality healthcare will remain elevated by an increasing and ageing population. This demand could provide opportunities ...

Apr, 2014 60 pages
Clinical Trial Management System Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2019 US$ 4,795.00

Clinical trial management system (CTMS) is a software solution for proper management, storage and analysis of drugs associated clinical data. CTMS is primarily ... trial protocols. This report provides an in-depth analysis of estimation of the CTMS market for the period 2013-2019, considering 2013 as the base ...

Apr, 2014 113 pages
Vaccine Development Strategies - Refocusing Efforts to Address New Challenges US$ 3,900.00

... , including recent activities of major pharmaceutical companies, insight into the challenges being faced by companies developing therapeutic vaccines and recommendations on clinical development strategies to overcome these potential obstacles and hurdles The report assesses the evolving competitive vaccines ...

Feb, 2014 60 pages
Global Hypertension Drugs Market 2014-2018 US$ 2,500.00

... treatment of pulmonary arterial hypertension and essential hypertension. TechNavio's report, the Global Hypertension Drugs Market 2014-2018, has been prepared ... Expirations. For a full, detailed list, view our report. Key Market Trend Increasing Focus on Combination Therapies. For a full, detailed list, ...

Apr, 2014 65 pages
Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Twinrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 67 pages
Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Recombivax HB (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion ...

Jan, 2014 68 pages
PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Schizophrenia - US Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating ... pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms ...

Feb, 2014 134 pages
PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

PharmaPoint: Schizophrenia - Japan Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, ... drive a significant period of growth over the forecast period. Disease management in Japan uses LAIs less often than the countries in the EU, and ...

Feb, 2014 133 pages
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 US$ 6,995.00

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, ... expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that ...

Feb, 2014 166 pages
Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Pediarix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 65 pages
Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Infanrix Hexa (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is ... well as a SWOT analysis. Sales forecast for Infanrix Hexa for top six countries from 2012 to 2022. Sales information covered for the US, ...

Jan, 2014 65 pages
Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are ...

Jan, 2014 66 pages
Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Heplisav (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 91 pages
Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Fendrix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people ...

Jan, 2014 64 pages
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia US$ 1,995.00

... - Indonesia Summary GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Indonesia”. It is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Indonesia ...

Apr, 2014 172 pages
Global Insulin Market Outlook 2018 US$ 1,200.00

... is forecasted to grow at a CAGR of over 10% during 2012-2018. Our RNCOS research report, “Global Insulin Market Outlook 2018”, has revealed that the ... comprehensive research work also studies how patent expiry of block buster insulin products would create opportunities for biosimilars. The report conducts an ...

Apr, 2014 55 pages
2014 Deep Research Report on Global and China Insulin Industry US$ 2,200.00

2014 Deep Research Report on Global and China Insulin Industry was professional and depth research report on Global and China Insulin ... application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis ...

Apr, 2014 126 pages
U.S. Pain Management Products & Services: A Market Analysis US$ 1,995.00

... suffer from chronic (long-term) pain. 700+ "pill mills" have emerged to serve Oxycontin addicts and profiteers, as 12 states have no drug monitoring ... data for multidisciplinary programs vs. anesthesiologists). New chapter covers the pain management devices market (TENS machines, spinal cord stimulators, pumps ...

Sep, 2010 246 pages
The U.S. Medical Marijuana Market US$ 995.00

... marijuana retail dispensaries now operating in the United States, operating in a very uncertain but improving environment. 20 states have legalized it, but “patients” must ... opinion and tax revenue-hungry states are fueling optimism about the medical marijuana (cannabis) market, but significant hurdles remain. ...

Oct, 2013 129 pages
Market Research Report on Global and Chinese Penicillin Industry, 2009-2019 US$ 2,400.00

... and Chinese Penicillin Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Penicillin industry. The report firstly ... report further analyzes quantitatively 2009-2014 global and China’s total market of Penicillin by calculation of main economic parameters of each company; The ...

Apr, 2014 150 pages
Pontine Glioma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Pontine Glioma. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Mar, 2014 95 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - US Drug Forecast and Market Analysis to 2022 US$ 4,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 136 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Japan Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Japan from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 89 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - Canada Drug Forecast and Market Analysis to 2022 US$ 4,995.00

... Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for the top drugs in Canada from 2012-2022. Analysis of the impact of key events as well the drivers ...

Jan, 2014 129 pages
PharmaPoint: Prophylactic Hepatitis B Virus Vaccines - 5EU Drug Forecast and Market Analysis to 2022 US$ 6,995.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 191 pages
Mast Cell Leukemia Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Trials Review, H1, 2014' provides data on the Mast Cell Leukemia clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Mar, 2014 127 pages
Malignant Glioma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Mar, 2014 93 pages
Malignant Ascites Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Malignant Ascites. It includes an overview of the trial numbers and their recruitment status as per the ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Mar, 2014 129 pages
Lymphoblastic Lymphoma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Lymphoblastic Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the ... many more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals ...

Mar, 2014 99 pages
Low-Grade Glioma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Trials Review, H1, 2014' provides data on the Low-Grade Glioma clinical trial scenario. This report provides elemental information and data relating ... Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Mar, 2014 74 pages
Low-Grade Astrocytoma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Review, H1, 2014' provides data on the Low-Grade Astrocytoma clinical trial scenario. This report provides elemental information and data relating ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Mar, 2014 104 pages
Engerix-B (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Engerix-B for top seven countries from 2012 to 2022. Sales information covered for the US, Canada, France, ...

Jan, 2014 67 pages
CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea US$ 1,995.00

... analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - South Korea”. The report is an essential source of ... process, the regulatory agencies and the approval processes for new drugs and medical devices Detailed analysis of the political and ...

Mar, 2014 261 pages
Comvax (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... analysis. Sales forecast for Comvax for the US from 2012 to 2022. Sales information covered for the US Reasons to buy Understand and ...

Jan, 2014 64 pages
Bimmugen (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

... B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that ... and chronic infections caused by all known strains of HBV. In 1988, Bimmugen became the first HBV vaccine available in Japan. The antigen ...

Jan, 2014 61 pages
B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Trials Review, H1, 2014' provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data ... scenario in BRIC nations Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type Listings of discontinued ...

Mar, 2014 203 pages
Ambirix (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022 US$ 3,495.00

Summary Hepatitis B, which is caused by the hepatitis B virus (HBV), is characterized by acute or chronic inflammation of the liver. Researchers and healthcare experts have estimated that roughly two billion people are infected with HBV worldwide, with roughly 600,000 people dying each year from HBV- ...

Jan, 2014 64 pages
Thesan Pharmaceuticals, Inc. - Product Pipeline Review - 2014 US$ 1,500.00

... and discontinued pipeline projects Latest company statement Latest news and deals relating to the Thesan Pharmaceuticals, Inc.’s pipeline products Reasons ... Assess the growth potential of Thesan Pharmaceuticals, Inc. in its therapy areas of focus Identify new drug targets and therapeutic classes in the ...

Feb, 2014 18 pages
1 2 3 4 5 >
Skip to top